MiR-654-5p attenuates breast cancer progression by targeting EPSTI1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNA (miRNA) dysregulation is implicated in various human diseases, including breast cancer.
• The specific role and clinical significance of miR-654-5p in breast cancer progression are not well understood.

Purpose of the Study:

• To investigate the expression levels, clinical relevance, and biological function of miR-654-5p in breast cancer.
• To identify the direct target of miR-654-5p and elucidate its mechanism in breast cancer progression.

Main Methods:

• Quantitative real-time PCR to assess miR-654-5p expression in breast cancer tissues and cell lines.
• Functional assays including cell growth, invasion, and apoptosis assays upon miR-654-5p overexpression.
• Luciferase reporter assays and Western blotting to validate EPSTI1 as a direct target of miR-654-5p.

Main Results:

• miR-654-5p was significantly downregulated in breast cancer specimens and cell lines.
• Low miR-654-5p expression correlated with advanced TNM stage, lymph node metastasis, and poor patient survival.
• Overexpression of miR-654-5p inhibited breast cancer cell growth and invasion while promoting apoptosis.
• EPSTI1 was identified as a direct target of miR-654-5p, with inverse expression correlation.
• EPSTI1 overexpression reversed the tumor-suppressive effects of miR-654-5p.

Conclusions:

• miR-654-5p functions as a tumor suppressor in breast cancer by directly targeting EPSTI1.
• The miR-654-5p/EPSTI1 axis represents a potential novel therapeutic target for breast cancer treatment.